A5079219158- Research on Leishmaniasis Studies
- Toxin Mechanisms and Immunotoxins
- Trypanosoma species research and implications
- Synthesis and Biological Evaluation
- Insect and Pesticide Research
- Metabolomics and Mass Spectrometry Studies
- Synthesis and biological activity
- Beetle Biology and Toxicology Studies
- Pharmacological Effects of Natural Compounds
- Food Allergy and Anaphylaxis Research
- Advanced Drug Delivery Systems
- Pharmacogenetics and Drug Metabolism
- Insect Pest Control Strategies
- Advancements in Transdermal Drug Delivery
Universidade Federal de Minas Gerais
2009-2024
Fundação Oswaldo Cruz
2015
Centro Universitário Newton Paiva
2009-2012
This work aimed to optimise a new nanoemulsion (NE) formulation loaded with Amphotericin B (AmB) and evaluate its in vivo antileishmanial activity vitro haemolytic toxicity. The influence of gradual increases pressure, using high-pressure homogeniser, was evaluated. NE characterised for droplet size, polydispersity index, zeta potential encapsulation efficiency (EE). For studies, AmB-NE administered intravenously mice infected by Leishmania infantum chagasi, which causes Visceral...
Cutaneous leishmaniasis (CL) is a neglected tropical skin disease caused by the protozoan genus Leishmania. The treatment restricted to handful number of drugs that exhibit toxic effects, limited efficacy, and drug resistance. Additionally, developing an effective topical still enormous unmet medical challenge. Natural oils, e.g. oleoresin from P. emarginatus fruits (SO), contain various bioactive molecules, especially terpenoid compounds such as diterpenes sesquiterpenes. However, its use...
Liposomal amphotericin B (AmB) or AmBisome® is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy limited in cutaneous (CL) HIV/VL co-infection. The aim of this work was to develop a formulation AmB PEGylated liposomes compare murine model CL. Formulations conventional were characterized particle size morphology, drug encapsulation efficiency aggregation state. Those compared Leishmania amazonensis-infected BALB/c mice their effects on...
Cutaneous leishmaniasis (CL) is a neglected tropical disease. The treatment restricted to drugs, such as meglumine antimoniate and amphotericin B, that exhibit toxic effects, high cost, long-term treatment, limited efficacy. development of new alternative therapies, including the identification effective drugs for topical oral CL, great interest. In this sense, combination photodynamic therapy (PDT) with chloroaluminum phthalocyanine liposomes (Lip-ClAlPc) administration self-emulsifying...
This study aimed to investigate the activity of a combination topical paromomycin gel and oral miltefosine for treatment experimental cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis. The efficacy combination, evaluated measuring lesion size parasite burden in skin spleen, was assessed BALB/c mice infected L. (L.) administered orally at 10 mg/kg body weight/day days, while 10% applied topically twice day 20 days. Treatment experimentally animals with paromomycin-oral...
ObjectivesThis study aimed to investigate the activity of combination topical paromomycin gel and oral miltefosine for treatment experimental cutaneous leishmaniasis caused by Leishmania (Leishmania) major.
To evaluate the in vitro activity and vivo efficacy of fexinidazole against main species that cause visceral cutaneous New World leishmaniasis.The inhibitory concentrations Leishmania (Leishmania) infantum chagasi, amazonensis (Viannia) braziliensis amastigotes were determined by assays. For evaluation, animals infected with L. (L.) amazonensis, (V.) or guyanensis divided into groups: (i) control; (ii) treated oral fexinidazole, from 50 to 300 mg/kg/day. leishmaniasis, size lesion was weekly...
Objectives: Cutaneous leishmaniasis is a neglected disease, associated with high morbidity, which partially due to the toxicity of available therapies. The pentavalent antimonial derivatives intralesional infiltration has proven be as effective intravenous drug-based therapy, however, there lack robust safety data.Methods: Phase II, uncontrolled, unicenter clinical trial assess profile standardized meglumine antimionate based on weekly infiltrations.Results: Fifty-three patients were...
Aim: To develop nanoemulsions (NEs) loading amphotericin B (AmB) and to evaluate the influence of different excipients on stability supramolecular organization, retention toxicity AmB. Materials & methods: The NEs were developed from oils, surfactants, external media anionic lipids (disteaoryl phosphatidylglycerol [DSPG] dioleoyl [DOPG]). Their impact size, pH, zeta potential, AmB encapsulation efficiency, hemolytic potential was evaluated. Results conclusion: use soybean oil (lipid matrix),...
Emetic tartar (ET), was used in the treatment of leishmaniasis but its use discontinued due to low therapeutic index. Liposomes have been shown be a promising strategy for delivery bioactive substances region interest, order reduce and/or eliminate undesirable effects. In present study, liposomes containing ET were prepared and characterized evaluate acute toxicity as well their leishmanicidal action using BALB/c mice with an inoculum Leishmania (Leishmania) infantum. composed egg...
This study aimed to evaluate the efficacy of binary combinations suboptimal schedules drugs with different administration routes (topical paromomycin, intramuscular meglumine antimoniate and oral miltefosine) treat animals infected Leishmania (Viannia) braziliensis. Hamsters were inoculated L. (V.) braziliensis after ulceration lesions, divided into seven groups: untreated control, miltefosine, antimoniate, + miltefosine paromomycin miltefosine. Meglumine administered at low doses topical a...
Aim: Amphotericin B (AmB) is an antileishmanial drug with high toxicity; however, this drawback might overcome by decreasing the AmB self-aggregation state. This work aimed at evaluating influence of cholesterol on aggregation state loaded in a nanoemulsion (NE-AmB) for treatment cutaneous leishmaniasis. NE-AmB (1, 4 and 8 mg/kg/day) was administered intravenously to animals infected Leishmania major every 2 days total five injections. Results: Ultraviolet-visible spectroscopy circular...
Metabolomics detects metabolic alterations associated with early AmB-induced nephrotoxicity and differences were observed by comparing conventional AmB (C-AmB) AmB-loaded NE.